Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: waverider who wrote (36857)	3/4/2002 1:22:58 PM
From: Dave Gore	Respond to of 99280

WAve, RESEARCH ALERT-King Pharmaceuticals raised to 'strong buy' PE is the lowest it's been in years. Long term growth as high as 30%: kevxml2a.infospace.com NEW YORK, March 4 (Reuters) - Merrill Lynch said Monday it raised its mid-term investment rating on King Pharmaceuticals Inc. (NYSE:KG - news) to ``strong buy'' from ``buy.'' Analyst Gregory Gilbert, in a research note, said the shares offer good value at a reasonable price. ``We believe that the current valuation reflects King's lack of internal research and development capabilities but does not reflect the visible and strong top and bottom line growth we expect to see over the next year or two,'' Gilbert wrote. He cited the company's Altac drug, an ACE inhibitor, which will be the subject of an upcoming direct-to-consumer advertising campaign, and Levoxyl, a drug used to treat hypothyroidism. King Pharmaceutical shares rose 70 cents to $30 in early trading on the New York Stock Exchange. plus this new: biz.yahoo.com I/R also reiterated strong growth when I spoke to them.